Dose Escalation Approved in ACCENT Clinical Trial of AMP945

• The ACCENT clinical trial assessing the efficacy of AMP945 in treating pancreatic cancer patients has now been approved for dose escalation and recruitment of third patient cohort. Melbourne, Australia:Amplia Therapeutics Limited (ASX: ATX) (“Amplia” or the “Company”) is pleased to advise that following a review of safety data collected to date, the ACCENT clinical trial’s Safety Review Committe